PMID- 25879458 OWN - NLM STAT- MEDLINE DCOM- 20160307 LR - 20220408 IS - 1742-2094 (Electronic) IS - 1742-2094 (Linking) VI - 12 DP - 2015 Mar 7 TI - Transiently lowering tumor necrosis factor-alpha synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice. PG - 45 LID - 10.1186/s12974-015-0237-4 [doi] LID - 45 AB - BACKGROUND: The treatment of traumatic brain injury (TBI) represents an unmet medical need, as no effective pharmacological treatment currently exists. The development of such a treatment requires a fundamental understanding of the pathophysiological mechanisms that underpin the sequelae resulting from TBI, particularly the ensuing neuronal cell death and cognitive impairments. Tumor necrosis factor-alpha (TNF-alpha) is a cytokine that is a master regulator of systemic and neuroinflammatory processes. TNF-alpha levels are reported to become rapidly elevated post TBI and, potentially, can lead to secondary neuronal damage. METHODS: To elucidate the role of TNF-alpha in TBI, particularly as a drug target, the present study evaluated (i) time-dependent TNF-alpha levels and (ii) markers of apoptosis and gliosis within the brain and related these to behavioral measures of 'well being' and cognition in a mouse closed head 50 g weight drop mild TBI (mTBI) model in the presence and absence of post-treatment with an experimental TNF-alpha synthesis inhibitor, 3,6'-dithiothalidomide. RESULTS: mTBI elevated brain TNF-alpha levels, which peaked at 12 h post injury and returned to baseline by 18 h. This was accompanied by a neuronal loss and an increase in astrocyte number (evaluated by neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) immunostaining), as well as an elevation in the apoptotic death marker BH3-interacting domain death agonist (BID) at 72 h. Selective impairments in measures of cognition, evaluated by novel object recognition and passive avoidance paradigms - without changes in well being, were evident at 7 days after injury. A single systemic treatment with the TNF-alpha synthesis inhibitor 3,6'-dithiothalidomide 1 h post injury prevented the mTBI-induced TNF-alpha elevation and fully ameliorated the neuronal loss (NeuN), elevations in astrocyte number (GFAP) and BID, and cognitive impairments. Cognitive impairments evident at 7 days after injury were prevented by treatment as late as 12 h post mTBI but were not reversed when treatment was delayed until 18 h. CONCLUSIONS: These results implicate that TNF-alpha in mTBI induced secondary brain damage and indicate that pharmacologically limiting the generation of TNF-alpha post mTBI may mitigate such damage, defining a time-dependent window of up to 12 h to achieve this reversal. FAU - Baratz, Renana AU - Baratz R AD - Department of Anatomy and Anthropology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. renanaba@post.tau.ac.il. FAU - Tweedie, David AU - Tweedie D AD - Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, BRC Room 05C220, 251 Bayview Blvd., Baltimore, MD, 21224, USA. tweedieda@grc.nia.nih.gov. FAU - Wang, Jia-Yi AU - Wang JY AD - Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan. jywang2010@tmu.edu.tw. FAU - Rubovitch, Vardit AU - Rubovitch V AD - Department of Anatomy and Anthropology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Rubovitc@post.tau.ac.il. FAU - Luo, Weiming AU - Luo W AD - Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, BRC Room 05C220, 251 Bayview Blvd., Baltimore, MD, 21224, USA. luowe@mail.nih.gov. FAU - Hoffer, Barry J AU - Hoffer BJ AD - Department of Neurosurgery, Case Western Reserve University School of Medicine, Cleveland, OH, USA. bjh82@case.edu. FAU - Greig, Nigel H AU - Greig NH AD - Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, BRC Room 05C220, 251 Bayview Blvd., Baltimore, MD, 21224, USA. greign@grc.nia.nih.gov. FAU - Pick, Chaim G AU - Pick CG AD - Department of Anatomy and Anthropology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. pickc@post.tau.ac.il. LA - eng GR - Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Intramural PT - Research Support, Non-U.S. Gov't DEP - 20150307 PL - England TA - J Neuroinflammation JT - Journal of neuroinflammation JID - 101222974 RN - 0 (3,6'-dithiothalidomide) RN - 0 (Tumor Necrosis Factor-alpha) RN - 4Z8R6ORS6L (Thalidomide) RN - EC 4.2.1.11 (Phosphopyruvate Hydratase) SB - IM MH - Animals MH - Apoptosis/drug effects MH - Brain/*pathology MH - Brain Injuries/*complications MH - *Cognition Disorders/metabolism/pathology/therapy MH - Disease Models, Animal MH - Enzyme-Linked Immunosorbent Assay MH - Male MH - Maze Learning/drug effects MH - Mice MH - Mice, Inbred ICR MH - Neurons/*enzymology MH - Phosphopyruvate Hydratase/metabolism MH - Recognition, Psychology/drug effects MH - Thalidomide/analogs & derivatives/chemistry/therapeutic use MH - Time Factors MH - Tumor Necrosis Factor-alpha/antagonists & inhibitors/*metabolism PMC - PMC4352276 EDAT- 2015/04/17 06:00 MHDA- 2016/03/08 06:00 PMCR- 2015/03/07 CRDT- 2015/04/17 06:00 PHST- 2014/12/16 00:00 [received] PHST- 2015/01/06 00:00 [accepted] PHST- 2015/04/17 06:00 [entrez] PHST- 2015/04/17 06:00 [pubmed] PHST- 2016/03/08 06:00 [medline] PHST- 2015/03/07 00:00 [pmc-release] AID - 10.1186/s12974-015-0237-4 [pii] AID - 237 [pii] AID - 10.1186/s12974-015-0237-4 [doi] PST - epublish SO - J Neuroinflammation. 2015 Mar 7;12:45. doi: 10.1186/s12974-015-0237-4.